Autopsy report · NCT05494697
Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC
Cause of deathFunding or business
“A business decision to place screening/enrollment on hold. Study redesign/amendment pending additional Ampligen-related data from an ongoing Phase I-II open label study (NCT05927142)”
Life of this trial
- Suspended: paused, and may or may not restart.
- 90 participants planned (an estimate, not an actual count).
Vital statistics
- Status
- Suspended
- Phase
- Phase 2
- Sponsor
- AIM ImmunoTech Inc.
- Sponsor type
- Industry
- Conditions
- Pancreatic Cancer
- Interventions
- Rintatolimod
- Participants
- 90 (planned, not actual)
- Sites
- 3
- Countries
- United States
Trials that died the same way
- A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy
“After a positive interim analysis, the decision was made to terminate the study early to allow for participants to enroll into an open label study” - Safety of SP-420 in the Treatment of Transfusional Iron Overload
“Study is on hold by FDA in the US.” - Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
“This study was closed to enrollment as of 13 May 2011 due to business reasons. Premature closure was not prompted by any safety or efficacy concerns.” - A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH (ARMOR)
“Interim analysis results from the open-label part of the study. The double blind portion of the study will be resumed once the study will continue.” - Characterization of the Pathogenesis of Primary and Secondary Lymphatic Disorders
“Study closed before total enrollment met.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.